Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Cash from Financing Activities (2023 - 2025)

Artiva Biotherapeutics (ARTV) has disclosed Cash from Financing Activities for 3 consecutive years, with -$121000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Financing Activities fell 303.33% to -$121000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $9000.0, a 100.0% decrease, with the full-year FY2025 number at $9000.0, down 99.99% from a year prior.
  • Cash from Financing Activities was -$121000.0 for Q4 2025 at Artiva Biotherapeutics, down from -$37000.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $163.9 million in Q3 2024 to a low of -$121000.0 in Q4 2025.
  • A 3-year average of $23.5 million and a median of $104500.0 in 2024 define the central range for Cash from Financing Activities.
  • Peak YoY movement for Cash from Financing Activities: skyrocketed 599.38% in 2024, then crashed 303.33% in 2025.
  • Artiva Biotherapeutics' Cash from Financing Activities stood at $962000.0 in 2023, then crashed by 103.12% to -$30000.0 in 2024, then plummeted by 303.33% to -$121000.0 in 2025.
  • Per Business Quant, the three most recent readings for ARTV's Cash from Financing Activities are -$121000.0 (Q4 2025), -$37000.0 (Q3 2025), and -$72000.0 (Q2 2025).